Merck: Buy This Bargain Before It's Gone

Deagreez/iStock via Getty Images On July 30, Merck (NYSE:MRK) released its financial results for the second quarter of 2024, which beat my and Wall Street analysts' expectations, thanks in part to strong sales of its cardiovascular franchise, as well as its blockbuster PD-1 inhibitor Keytruda, which has already been approved for 40 indications in the U.S. In this article, I will discuss in detail several topics that are stirring the minds of financial market participants, ranging from the reasons behind ...